Xenon to Report Q2 2025 Financial Results on August 11, 2025

Rhea-AI Summary

Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, will report its Q2 2025 financial results on Monday, August 11, 2025, after U.S. market close. The company will host a conference call at 4:30 PM ET to discuss results and provide business updates.

Xenon is advancing an ion channel product portfolio focused on epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025.

Conference Call/Webcast Information:

Date:		Monday, August 11, 2025
Time:		4:30 pm Eastern Time (1:30 pm Pacific Time)
Webcast:		Pre-register here
Dial-In:		(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:		4102397

A live webcast of the company presentation will be available on the Investors section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When will Xenon (XENE) report Q2 2025 earnings?

Xenon will report Q2 2025 earnings on Monday, August 11, 2025 after U.S. market close, followed by a conference call at 4:30 PM ET.

How can investors access Xenon's Q2 2025 earnings call?

Investors can access the call via webcast through pre-registration or by dialing (800) 715-9871 (toll-free) or (646) 307-1963 (international) with Conference ID: 4102397.

What is Xenon's lead drug candidate?

Xenon's lead candidate is azetukalner, a novel Kv7 potassium channel opener in late-stage clinical development for multiple indications.

What therapeutic areas does Xenon focus on?

Xenon focuses on neuroscience therapeutics, specifically developing treatments for epilepsy and depression through their ion channel product portfolio.